CN103845311A - New medical use of resveratrol - Google Patents
New medical use of resveratrol Download PDFInfo
- Publication number
- CN103845311A CN103845311A CN201210494471.3A CN201210494471A CN103845311A CN 103845311 A CN103845311 A CN 103845311A CN 201210494471 A CN201210494471 A CN 201210494471A CN 103845311 A CN103845311 A CN 103845311A
- Authority
- CN
- China
- Prior art keywords
- alcohol
- herba chenopodii
- resveratrol
- white reed
- reed herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides an application of resveratrol in preparation of drugs for promoting post-surgery intestinal function restoring. According to the present invention, with intravenous administration of the resveratrol, a significant inhibition effect is provided for acute inflammation exudation, no significant influence on gastric emptying is generated, and enterocinesia of the enterocinesia slowing animal model can be significantly accelerated.
Description
technical field
The present invention relates to white reed Herba chenopodii alcohol in the application for the preparation of promoting in postoperative intestine functional recovery medicine.
Background technology
Abdominal operation is the modal operation of surgery, and the intestinal function of general patients after surgery is weaker, and the rehabilitation of the recovery of postoperative intestine functional to patient, comprises the recovery from illness of disease, reduces the complication such as intestinal adhesion, all significant.
Recovering postoperative intestinal function, is mainly the enterokinesia that recovers some strength, but owing to can not taking food after operation, therefore the too early wriggling of stomach, may cause epigastric discomfort without food because of gastric.Bibliographical information, there is the ratio of intestinal adhesion in various degree up to 80-90%[Menies D in abdominal postoperative, Ellis H.Intestinal obstruction from adhesion how big is the problem.Ann R Coll Surg Engl, 1990,72:60], the fibrin oozing out after operation, within 10 hours, rise and start to form fiber adhesion, and the generation of intestinal adhesion is crossed weak relevant with postoperative Abdominal effusion and enterokinesia, reduce and ooze out or improve wriggling, can reduce the generation of adhesion.
At present, digestive tract power medicine, to gastrointestinal, particularly the effect of stomach is excessively strong, is unsuitable for the recovery of hands gastrointestinal function recovery after operation.
Therefore find a kind of Treatment defect that had not only been conducive to the recovery of postoperative intestinal function but also can have overcome existing medicine and become one of important topic of medical research instantly.
Resveratrol, have another name called resvertrol, 3,4', 5-resveratrol, (E)-5-2-(4-hydroxyphenyl)-vinyl-Resorcinol, chemical formula (molecular formula): C14H12O3, it is a kind of white powder, being that one has important physiologically active polyphenols, is main composition in various plants body, can be widely used in food, health product, medicine and other fields.Pharmacological action: the generation of anti-bacteria and anti-virus, antitumor, anti-hepatitis, inhibition platelet aggregation and thromboxane B2.It can stop the oxidation of low density lipoprotein, LDL, has potential prevention and cure of cardiovascular disease, anti-cancer, antiviral and immunoregulation effect, and its effect main manifestations is: anticoagulant, regulate the content of Blood Cholesterol, antibacterial action, antitumaous effect, anti-aging effects.But the effect about white reed Herba chenopodii alcohol with treatment post-operative recovery intestinal function has no report; Given this, the inventor, by a large amount of experimentatioies, provides the application of white reed Herba chenopodii alcohol in the medicine of preparing intestinal function recovery after iatrotechnics.
Summary of the invention
The invention provides the application of white reed Herba chenopodii alcohol in the medicine recovering for the preparation of promotion postoperative intestine functional.
The invention provides the pharmaceutical composition that is used for the treatment of postoperative intestinal function recovery being formed by white reed Herba chenopodii alcohol and pharmaceutically acceptable carrier or adjuvant.
White reed Herba chenopodii alcohol provided by the invention is when for postoperative intestinal function recovery, and its administering mode is for being intravenously administrable (comprising intravenous injection and intravenous drip).
White reed Herba chenopodii alcohol provided by the invention is when for postoperative intestinal function recovery, and its dosage scope is: 50-5000mg.
Our pharmacological research finds, white reed Herba chenopodii alcohol intravenously administrable oozes out and has obvious inhibitory action acute inflammation, and gastric emptying is had no significant effect, and can obviously accelerate the slow down enterokinesia of animal pattern of enterokinesia.After operation, (operation after 1-3 days) vein gives white reed Herba chenopodii alcohol early stage, can obviously shorten postoperative intestine ring sound recovery time, and aerofluxus and defecation time in advance, show that white reed Herba chenopodii alcohol can alleviate inflammatory reaction, reduce inflammatory exudation, promote enterokinesia to recover.The advantages such as the white reed Herba chenopodii of the present invention alcohol has good effect, and side effect is low.
The present invention confirms that by following test white reed Herba chenopodii alcohol has the effect of intestinal function recovery after iatrotechnics.
Detailed description of the invention
preparation example 1 is prepared white reed Herba chenopodii alcohol freeze-dried powder
Under cleaning condition, get white reed Herba chenopodii alcohol 50g, be dissolved in 1000 ml waters for injection, add 100 g low molecular dextrans, stirring and dissolving, ultrafiltration, obtains apyrogenic clear liquor, every 1.0ml, by the lyophilizing of freeze-dried powder technique, makes every freeze-dried powder containing 50 mg.
preparation example 2 is prepared white reed Herba chenopodii alcohol injection
Under cleaning condition, get white reed Herba chenopodii alcohol 100 g, be dissolved in 5000 ml waters for injection, stirring and dissolving, ultrafiltration, obtains apyrogenic clear liquor, by injection preparation technology, makes mono-of 5ml, containing the injection of white reed Herba chenopodii alcohol 100 mg.
the impact that the white reed Herba chenopodii alcohol of test example 1 promotes small intestine movement of mice
1.1 experiment material
Motilium: (10mg/ grain, Xian-Janssen Pharmaceutical Ltd.);
Clean level Kunming mouse, body weight 18 g～22 g, male and female half and half.
1.2 experimental techniques and result
Get 80 of mices, male and female half and half, fasting 12 hours, random 8 groups, be respectively white reed Herba chenopodii alcohol 5 mg/kg groups, white reed Herba chenopodii alcohol 10 mg/kg groups, white reed Herba chenopodii alcohol 20 mg/kg groups, white reed Herba chenopodii alcohol 250 mg/kg groups, white reed Herba chenopodii alcohol 500 mg/kg groups, white reed Herba chenopodii alcohol 1000 mg/kg groups, motilium group, blank group.After the white each vein group of reed Herba chenopodii alcohol administration 30 minutes, gavage respectively containing 5% Insta-Char, motilium group gavages the suspension containing 5% active carbon of 1mg/ml motilium, and blank group gavages containing 5% Insta-Char simultaneously.Within 20 minutes, put to death mice, the taking-up intestinal tube of cutting open the belly, measure pylorus to the distance in active carbon forward position as " advance distance in active carbon intestinal ", measure pylorus to the distance of caecum as full intestinal length, be calculated as follows: advance distance (cm) in active carbon propelling rate=active carbon intestinal/full intestinal length (cm) 100%, t inspection between each group active carbon propelling rate employing group, carries out statistical procedures.
Table 1 result shows, the active carbon propelling rate that white reed Herba chenopodii alcohol 10 mg/kg intravenous administration groups are obviously strengthened small intestine movement of mice is (with the comparison of blank group, P<0.05), white reed Herba chenopodii alcohol 20 mg/kg, white reed Herba chenopodii alcohol 250 mg/kg, white reed Herba chenopodii alcohol 500 mg/kg, white reed Herba chenopodii alcohol 1000 mg/kg intravenous administrations, obviously strengthen the active carbon propelling rate (with the comparison of blank group, P<0.01) of small intestine movement of mice.
The impact that the white reed Herba chenopodii alcohol of table 1 advances small intestine movement of mice
△ △: P<0.01;
△: P<0.05, with the comparison of blank group.
Claims (2)
1. the application of white reed Herba chenopodii alcohol in the medicine recovering for the preparation of promotion postoperative intestine functional.
2. the pharmaceutical composition being formed by white reed Herba chenopodii alcohol and pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210494471.3A CN103845311A (en) | 2012-11-28 | 2012-11-28 | New medical use of resveratrol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210494471.3A CN103845311A (en) | 2012-11-28 | 2012-11-28 | New medical use of resveratrol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103845311A true CN103845311A (en) | 2014-06-11 |
Family
ID=50853719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210494471.3A Pending CN103845311A (en) | 2012-11-28 | 2012-11-28 | New medical use of resveratrol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103845311A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739812A (en) * | 2015-02-10 | 2015-07-01 | 河北工业大学 | Pharmaceutical composition containing resveratrol and application of pharmaceutical composition |
| CN106389395A (en) * | 2016-10-21 | 2017-02-15 | 温州市人民医院 | Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) |
-
2012
- 2012-11-28 CN CN201210494471.3A patent/CN103845311A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739812A (en) * | 2015-02-10 | 2015-07-01 | 河北工业大学 | Pharmaceutical composition containing resveratrol and application of pharmaceutical composition |
| CN106389395A (en) * | 2016-10-21 | 2017-02-15 | 温州市人民医院 | Use of resveratrol in preparation of drug for treating irritable bowel syndrome (IBS) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105324114B (en) | Astaxanthin anti-inflammatory synergistic combination | |
| RU2681930C2 (en) | Application of andrographolide in preparation of pharmaceutical drug for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
| CN105636584A (en) | Method for use of vitamin b composition to promote motility of gastrointestinal system | |
| CN112370470A (en) | Microecological preparation for reconstructing intestinal microecology | |
| CN103450468A (en) | PEGylated artesunate derivatives, and pharmaceutical compositions and uses thereof | |
| CN114392256A (en) | Application of cyanidin in preventing and treating vascular calcification | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN103845311A (en) | New medical use of resveratrol | |
| Ye et al. | Subsegmental bowel enteral nutrition infusion and succus entericus reinfusion in patients with severe acute pancreatitis complicated with multiple enteric fistulae: a successful experience | |
| CN107684554B (en) | Application of the butyric acid compound in preparation prevention and treatment NEC drug | |
| CN112755035A (en) | Application of tauroursodeoxycholic acid in treatment of neonatal necrotizing enterocolitis | |
| JP6257031B2 (en) | Prevention or treatment of urinary tract infections | |
| JP2024504555A (en) | Use of norharman in the manufacture of drugs for the prevention and treatment of acute pancreatitis | |
| CN108904484A (en) | A kind of purposes of progallin A | |
| CN110721202B (en) | Fecal bacteria capsule and preparation method thereof | |
| CN1679542A (en) | Frozen powder injection of silybin and its preparing method | |
| Azzopardi et al. | Proton pump inhibitors in the management of tachypnoea following panproctocolectomy: a case of high output ileostomy | |
| US20140199346A1 (en) | Therapeutic agent for influenza virus infection diseases | |
| CN107335059B (en) | Use of DSPE-PEG polymer as oral and transpulmonary absorption promoter | |
| Hill, ID, Mann, MD & Bowie | Successful management of persistent diarrhoea in infants | |
| CN110898052A (en) | Application of kaempferol in preparation of medicine for treating sepsis | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| CN1277533C (en) | Use of archin and extracts containing archin in recovery of enterogastric functions after operation and prevention of intestinal edhension | |
| KR20230113576A (en) | Parenteral nutritional formulations containing arginine butyrate | |
| ES2955633A1 (en) | Composition for intestinal rehabilitation (Machine-translation by Google Translate, not legally binding) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140611 |